Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
View Patent ↗The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method of identifying a human having an increased risk for developing recurrent myocardial infarction, comprising testing a nucleic acid sample from said human for the presence or absence of a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 21398 or its complement thereof, wherein the presence of at least one G allele at the SNP identifies said human as having an increased risk for recurrent myocardial infarction as compared to a human with two A alleles at the SNP.
2. The method of claim 1 in which SEQ ID NO: 21398 is a segment of the genomic sequence of LRP2 gene comprising SEQ ID NO: 17581.
3. The method of claim 2 in which the SNP is located at position 208593 of SEQ ID NO: 17581.
4. The method of claim 1 in which said nucleic acid sample is extracted from a biological sample.
5. The method of claim 4 in which said biological sample is blood, saliva, or buccal cells.
6. The method of claim 1 in which said nucleic acid sample is amplified before the testing is carried out.
7. The method of claim 1 in which the testing is carried out by using detection reagents comprising the nucleotide sequences of SEQ ID NO: 73293, SEQ ID NO: 73294, and SEQ ID NO: 73295.
8. The method of claim 1 in which the testing is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.
9. A method of identifying a human having a decreased risk for developing recurrent myocardial infarction, comprising testing a nucleic acid sample from said human for the presence or absence of a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 21398 or its complement thereof, wherein the presence of two A alleles at the SNP identifies said human as having a decreased risk for recurrent myocardial infarction as compared to a human with at least one G allele at the SNP.
10. The method of claim 9 in which SEQ ID NO: 21398 is a segment of the genomic sequence of LRP2 gene comprising SEQ ID NO: 17581.
11. The method of claim 10 in which the SNP is located at position 208593 of SEQ ID NO: 17581.
12. The method of claim 9 in which said nucleic acid sample is extracted from a biological sample.
13. The method of claim 12 in which said biological sample is blood, saliva, or buccal cells.
14. The method of claim 9 in which said nucleic acid sample is amplified before the testing is carried out.
15. The method of claim 9 in which the testing is carried out by using detection reagents comprising the nucleotide sequences of SEQ ID NO: 73293, SEQ ID NO: 73294, and SEQ ID NO: 73295.
16. The method of claim 9 in which the testing is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele- specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.
17. A method of determining a human's risk for developing recurrent myocardial infarction, comprising testing a nucleic acid sample from said human for the presence or absence of a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 21398 or its complement thereof, wherein the presence of at least one G allele at the SNP identifies said human as having an increased risk for recurrent myocardial infarction as compared to a human with two A alleles at the SNP, or the presence of two A alleles at the SNP identifies said human as having a decreased risk for recurrent myocardial infarction as compared to a human with at least one G allele at the SNP.
18. The method of claim 17 in which SEQ ID NO: 21398 is a segment of the genomic sequence of LRP2 gene comprising SEQ ID NO: 17581.
19. The method of claim 18 in which the SNP is located at position 208593 of SEQ ID NO: 17581.
20. The method of claim 17 in which said nucleic acid sample is extracted from a biological sample.
21. The method of claim 20 in which said biological sample is blood, saliva, or buccal cells.
22. The method of claim 17 in which said nucleic acid sample is amplified before the testing is carried out.
23. The method of claim 17 in which the testing is carried out by using detection reagents comprising the nucleotide sequences of SEQ ID NO: 73293, SEQ ID NO: 73294, and SEQ ID NO: 73295.
24. The method of claim 17 in which the testing is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.